DicoverX Introduces KILR Assay Platform

DiscoverX has launched its KILR Retroparticles platform to facilitate the development of cytotoxicity assays in most cell lines, the Fremont, Calif-based company announced Tuesday.

Versus traditional assays, the platform tackles the challenges of lack of throughput, sensitivity and specificity in measurement, the company says.

The assay features an “add-and-read protocol” for fast screening, lead optimization, characterization and QC lot release applications for protein and cellular therapies in cancer immunotherapy, according to company CEO Todd Nelson. — Anisa Jibrell